Transplantation Conditioning
"Transplantation Conditioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
| Descriptor ID |
D019172
|
| MeSH Number(s) |
E02.095.465.425.450.800 E05.478.610.800
|
| Concept/Terms |
Transplantation Conditioning- Transplantation Conditioning
- Conditioning, Transplantation
- Conditionings, Transplantation
- Transplantation Conditionings
|
Below are MeSH descriptors whose meaning is more general than "Transplantation Conditioning".
Below are MeSH descriptors whose meaning is more specific than "Transplantation Conditioning".
This graph shows the total number of publications written about "Transplantation Conditioning" by people in this website by year, and whether "Transplantation Conditioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 2 | 6 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 0 | 5 | 5 |
| 2008 | 7 | 3 | 10 |
| 2009 | 3 | 6 | 9 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 4 | 5 |
| 2012 | 3 | 4 | 7 |
| 2013 | 2 | 2 | 4 |
| 2014 | 6 | 3 | 9 |
| 2015 | 13 | 5 | 18 |
| 2016 | 4 | 0 | 4 |
| 2017 | 8 | 7 | 15 |
| 2018 | 11 | 8 | 19 |
| 2019 | 10 | 3 | 13 |
| 2020 | 3 | 13 | 16 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 8 | 8 |
| 2024 | 3 | 5 | 8 |
| 2025 | 4 | 2 | 6 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transplantation Conditioning" by people in Profiles.
-
Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28; 10(8):2698-2710.
-
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant. 2026 May; 61(5):591-600.
-
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood Adv. 2026 Mar 10; 10(5):1783-1798.
-
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm. Bone Marrow Transplant. 2026 Mar; 61(3):333-340.
-
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2026 Jan; 61(1):36-43.
-
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplant Cell Ther. 2025 Oct; 31(10):826.e1-826.e10.
-
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy. Haematologica. 2025 Nov 01; 110(11):2635-2646.
-
Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan. Transplant Cell Ther. 2025 Jun; 31(6):382.e1-382.e17.
-
A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD. Ann Hematol. 2025 Mar; 104(3):1917-1929.
-
Increased Non-Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan-Based Regimen. Eur J Haematol. 2025 May; 114(5):852-863.